Windtree Therapeutics, Inc. Share Price & Technical Analysis
WINT · $0.01 (-50.00%)
Healthcare / Biotechnology
$0.01
-50.00%
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surf…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 | -63% | -51% | -59% | -8% | -33% | -29% | 40% | -83% | 0% | 0% | -100% | – | -386% |
| 24 | -39% | -18% | -3% | -17% | -26% | -12% | 185% | -8% | -69% | -69% | -24% | -34% | -134% |
| 23 | -11% | -21% | -17% | -66% | -16% | -2% | 8% | -21% | -16% | 12% | 12% | -35% | -175% |
| 22 | -29% | -3% | 8% | -34% | -35% | -19% | -9% | 0% | -25% | -43% | 6% | -15% | -199% |
| 21 | 11% | -10% | -52% | -10% | -20% | 29% | -17% | 5% | 7% | -13% | -4% | -6% | -82% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Exhausted
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$559.57K
P/E ratio
0
52W high
$1.86
52W low
$0.01
Volume
92,793
Beta
1.76
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Windtree Therapeutics, Inc. share price today?
- Windtree Therapeutics, Inc. (WINT) last traded around $0.01 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does WINT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for WINT. Download the app for real-time alerts.
- How can I analyze Windtree Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.